1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Electronic Drug Registration and Listing (eDRLS) Using CDER Direct - 2023 - 09/28/2023
  1. News & Events for Human Drugs

Conference | Virtual

Event Title
Electronic Drug Registration and Listing (eDRLS) Using CDER Direct - 2023
September 28, 2023


Date:
September 28, 2023
Time:
8:45 a.m. - 4:45 p.m. ET

Topics & PresentationsSpeakers
Electronic Drug Registration and Listing (eDRLS) Using CDER Direct – 2023 – Part 1 
Keynote.pdfJill Furman, JD
Director
Office of Compliance (OC)
Center for Drug Evaluation and Research (CDER) | FDA
How to Submit an Establishment Registration.pdfRegie Samuel
Technical Information Specialist
Drug Registration and Listing Branch (DRLB)
Division of Labeling, Registration and Unapproved Drugs (DLRUD)
Office of Unapproved Drugs and Labeling Compliance (OUDLC)
OC | CDER | FDA
Using the Appropriate Business Operation(s) and Business Qualifier(s).pdfJose Cabrera
Information Technology Specialist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Establishment Registration Renewal, Updates, and De-Registration.pdfRegie Samuel
U.S. Agents and Official Contacts.pdfJose Cabrera
CDER Direct Labeler Code Request Demo.pdfSoo Jin Park
LCDR, USPHS
Regulatory Officer
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Who Will Be Assigned a Labeler Code and Who Won’t.pdfLaurie Simonds, GWCPM
Technical Information Specialist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Labeler Code Inactivation and Reactivation.pdfLalnunpuii Huber
Technical Information Specialist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Updates, Mergers, and Acquisitions.pdfLaurie Simonds
Electronic Drug Registration and Listing (eDRLS) Using CDER Direct – 2023 – Part 2 
CDER Direct Drug Listing.pdfTroy Cu
Technical Information Specialist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Listing a Combination Product.pdfTroy Cu
Strength Conversion in Drug Listing.pdfLeyla Rahjou-Esfandiary
Lead Consumer Safety Officer
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Listing Updates and Delisting.pdfYogesh Paruthi
Consumer Safety Officer
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Blanket No Change Certification.pdfVikas Arora
Pharmacist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
503B Registration and Product Reporting Using CDER Direct.pdfHuascar Batista
Senior Advisor
Office of Compounding Quality and Compliance (OCQO)
Office of Compliance (OC) | CDER | FDA
Q&A Discussion PanelTroy Cu, Leyla Rahjou-Esfandiary, Yogesh Paruthi, Vikas Arora, Huascar Batista, Regie Samuel, Soo Jin Park, Laurie Simonds, and Lalnunpuii Huber
Electronic Drug Registration and Listing (eDRLS) Using CDER Direct – 2023 – Part 3 
OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2023 User Fees and Registration.pdfYajun (Jason) Tu, PharmD, PhD, BCSCP
LCDR, USPHS
Program Management Officer
Policy and Operations Branch (POB)
Division of User Fee Management (DUFM)
Office of Management (OM) | CDER | FDA
National Drug Code (NDC) Reservation.pdfDavid Mazyck
Consumer Safety Officer
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Format of the National Drug Code.pdfJulian Chun
Pharmacist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
NDC Assignment to Drugs.pdfSoo Jin Park
LCDR, USPHS
Regulatory Officer
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Untitled Letters and Warnings .pdf                    Tasneem Hussain
Pharmacist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Data Inactivation.pdfVikas Arora
Pharmacist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Data Removals and Flags.pdfTasneem Hussain
Downstream Effects.pdfLeyla Rahjou-Esfandiary
Lead Consumer Safety Officer
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Electronic Drug Registration and Listing (eDRLS) Using CDER Direct – 2023 – Part 4 
Recent Automated Validation Rules.pdfLalnunpuii Huber
Technical Information Specialist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Case Studies.pdfJulian Chun
Pharmacist
DRLB | DLRUD | OUDLC | OC | CDER | FDA
Q&A Discussion PanelLalnunpuii Huber, Julian Chun, Yajun (Jason) Tu, David Mazyck, Soo Jin Park, Tasneem Hussain, Vikas Arora, Leyla Rahjou-Esfandiary

 

Agenda

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS EVENT

This conference is intended to provide basic instruction in the registration and listing policy and process for those who are new to this regulatory program as well as offer regulatory professionals more in-depth information on issues and current events affecting Drug Registration and Listing. FDA will provide:

  • A demonstration on how-to submit establishment registration and drug listing data using CDER Direct
  • An overview on registration and listing regulatory requirements and compliance framework
  • Case studies for an interactive learning experience at the end of the day

INTENDED AUDIENCE

  • Regulatory science and regulatory affairs professionals working on establishment registration and drug listing submissions and data compliance.
  • Consultants focused on SPL submissions to FDA.
  • Healthcare professionals using drug listing data and downstream databases to access prescribing and labeling information.
  • Foreign drug manufacturers and importers that manufacture and import drugs for US commercial distribution.

TOPICS COVERED

  • Explaining the latest proposed rule on the National Drug Code (NDC).
  • Learning about the current automated validation rules for registration and listing submissions.
  • Providing accurate registration and listing data to avoid submission errors, deficiency letters, manual overrides, and more.

LEARNING OBJECTIVES

  • Explain who must register and list.
  • Provide an overview to FDA’s registration and listing compliance program.
  • Explain how the strength conversion is calculated in listing SPLs.
  • Describe the formats and segments of the National Drug Code (NDC).

FDA RESOURCES

 

Back to Top